Chroma Medicine announces the formation of a Scientific Advisory Board of global experts in gene editing, cell therapy and gene therapy

members Bradley BernsteinMasters, Ph.D., Paula CannonPh.D. Howard ChangMD, PhD, and Ahmed (Moe) KhalilPh.D., will direct the development of the company’s key software and epigenetic editing platform

Scientific advisors join the founders of Chroma, Luke GilbertPh.D. Keith Jong MD., Ph.D., David LiuPh.D. Angelo LombardoPh.D. Luigi NaldiniMD, PhD, and Jonathan WisemanPh.D., expanding the company’s world-class team of pioneers in genomic medicine

Cambridge, Massachusetts.And the September 20 2022 /PRNewswire/- medicine chromaChroma, the genomic medicine company leading in single-dose gene-editing therapies, today announced the formation of a Scientific Advisory Board (SAB) comprising of renowned leaders in epigenetics, cell and gene therapy, and synthetic biology: Bradley BernsteinMasters, Ph.D., Paula CannonPh.D. Howard ChangMD, PhD, and Ahmed (Moe) Khalil, Ph.D. SAB members will provide key input to Chroma as the company develops its programs to treat a wide range of diseases.

“Each of these distinguished experts will be useful as we unlock the potential of epigenetic editing therapies,” he said. Katherine Stemann BrinMD, CEO of Chroma Medicine. “We are honored to welcome them to the Chroma team and look forward to drawing on their expertise as we build the future of genomic medicine.”

“The SAB is made up of scientific leaders whose basic research has greatly advanced the areas of genome editing, cell therapy and genetics,” he said. Vic Meyer, Ph.D., president and chief scientific officer of Chroma. “They bring a wealth of knowledge and experience to Chroma as we continue to develop our platform with the goal of delivering new, single-dose genomic therapies to patients.”

Members of the Chroma Scientific Advisory Board are:

  • Bradley BernsteinMasters, Ph.D.
    • Dr. Bradley Bernstein He is the chair of cancer biology at the Dana-Farber Cancer Institute, director of the Gene Regulatory Observatory at the Broad Institute, and professor of cell biology and pathology at Harvard Medical Schooland investigated Harvard Ludwig Institute. His research, focused on epigenetic gene regulation, led to the discovery of “bivalent domains,” a distinct chromatin state consisting of opposite histone modifications that defines key genes for an alternative fate. Dr. Bernstein received his master’s and doctoral degrees. From University of Washington.
  • Paula CannonPh.D.
    • Dr. Paula Cannon He is a Distinguished Professor in the Department of Molecular Microbiology and Immunology at University of Southern California Keck School of Medicine. She leads a research team that studies viruses, stem cells, and gene therapy. Her work led to the development of a gene-editing approach to treating HIV, which is currently undergoing clinical trials. Her recent contributions focus on the use of CRISPR/Cas9 to engineer hematopoietic stem cells and B cells, with the goal of long-term control of viral infection. Dr. Cannon received her Ph.D. In the genetics of University of Liverpool.
  • Howard ChangMasters, Ph.D.
    • Dr. Howard Chang Do you Virginia and DK Ludwig Professor of Cancer Research and Professor of Dermatology and Genetics at Stanford University. His research pioneered methods of epigenetic profiling and identification of key regulators of large-scale transcription programs. Dr. Zhang received his Ph.D. in biology from Massachusetts Institute of Technology and his doctor from Harvard Medical School.
  • Ahmed (Moe) KhalilPh.D.
    • Dr. Ahmed (Moe) Khalil He is the Dorf-Ebner Distinguished Professor of Biomedical Engineering and Co-Director of the Center for Biological Design at Boston Universityand a visiting scholar at the Wyss Institute for Biologically Inspired Engineering in Harvard university. His research pioneered synthetic biology methods for dissecting and engineering the molecular circuits that control gene regulation and epigenetic memory in eukaryotes. Dr. Khalil received his Ph.D. in mechanical engineering from Massachusetts Institute of Technology.

About Chroma Medicine

Chroma Medicine is a biotechnology company pioneering a new class of genomic drugs that harnesses epigenetics, the innate mechanism of gene regulation, to deliver single-dose treatments to patients with genetically driven diseases. The company was founded by the world’s leading experts in genetic research and led by a veteran team of industry leaders and scientists with deep expertise in genetic medicine and drug discovery and development. For more information, please visit or follow the company on LinkedIn and Twitter.

Source: Chroma Medicine

Leave a Comment